Kurzfassung

A randomized, multicenter, double-blind, phase 3 trial comparing the efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in subjects with newly diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)